Olema Oncology previews Phase III trial plans for dual-mechanism SERD in breast cancer
In an exclusive, Olema CEO Sean Bohen discusses plans for two late-stage trials of OP-1250 in ER+, HER2- breast cancer in 2023 and 2024.
By
William Newton
William Newton is a Senior Reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing on clinical trial design, rare diseases, and the central nervous system. Now based in New York City, he previously covered diabetes drug development at Close Concerns’ industry-facing publication in San Francisco. William holds a BA in Economics from Williams College.
Latest articles
All Articles
Mapping Endpoints in Psoriasis: beyond the mirage of complete skin clearance
As plaque psoriasis treatments prove more effective, the field is debating new approaches to measure efficacy and address remaining…
By
AIM ImmunoTech outlines Phase II study plans for long Covid fatigue
AIM ImmunoTech leadership offers new details on a potential Phase II trial of Ampligen in long Covid patients with…
By
Ashvattha previews plans for long Covid trial in mid-2023
In an exclusive, Ashvattha Therapeutics CEO Jeff Cleland discusses a potential trial of OP-101 in long Covid patients experiencing…
By
Plaque psoriasis and psoriatic arthritis: trials to watch in 2022
Four Phase II and III trials in plaque psoriasis or psoriatic arthritis have results expected in 2H 2022, and…
By
Axcella previews long Covid registrational trial plans in UK and US
Axcella in discussions with UK regulators for a new long Covid trial, CEO says, following Phase IIa results announced…
By
Alzheimer’s disease: charting amyloid theory trials amidst another controversy
After reports of possible image fabrication in studies supporting the amyloid theory for Alzheimer’s disease, we break down the…
By
Phase 0 clinical trials: what you need to know
Clinical Trials Arena breaks down the two most common types of Phase 0 trials, including window of opportunity trials…
By
Glioblastoma: are Phase 0 trials a window of opportunity in drug development?
Despite key advantages to Phase 0 trials in glioblastoma, sponsors have been hesitant to employ the design.
By